Tumoural expression of PD-L1 prior to therapy does not correlate with response
tumours, tumour
TUMOURS, SECONDARY, TUMOUR
At baseline in the efficacy-evaluable population who had available tissue for staining, 1/14 tumours (7%) was classified as PD-L1 positive (≥1% PD-L1 expression). Per secondary endpoint analyses, there was no correlation between baseline PD-L1 expression and response; tumour size reductions were seen in PD-L1 positive and negative tumours (Fig. 